Depression

7 trials 3 recruiting MedDRA PT
7 Registered trials
3 Recruiting
7 Unique sponsors
9 Unique IMPs
2 Commercial trials
Drug classes (ATC)
ATC code not specified 5
N Neurology/Psychiatry (ATC N) 2
Mechanism of action (INN-stem analysis)
Unknown / small molecule 9 substances
Phase II: 4 Phase IV: 1 Phase I: 1 Other: 1

Filter these 7 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 7 trials

Phase II

4 trials
  • Centre Hospitalier Universitaire Grenoble Alpes Academic
    ESCITALOPRAM; PRUCALOPRIDE SUCCINATE
    2025-521811-38-01 1 country n=70
    Pending
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS Academic
    [18F]MC225
    2023-508303-20-01 1 country 2025 n=44
    Recruiting
  • Narodni Ustav Dusevniho Zdravi Academic
    KETAMINE HYDROCHLORIDE; MIDAZOLAM; PSILOCYBINE
    2024-517747-31-00 1 country 2022 n=60
    Recruiting
  • University Of Gothenburg Academic
    3-(3-METHANESULFONYL-PHENYL)-1-PROPYL-PIPERIDINE HYDROCHLORIDE; PLACEBO
    2024-513894-35-00 1 country n=180
    Pending

Phase IV

1 trial
  • Azienda Socio Sanitaria Territoriale Di Lodi Academic
    CHOLINE ALFOSCERATE
    2025-520899-25-00 1 country 2024 n=20
    Recruiting

Phase I

1 trial
  • Lophora ApS Commercial
    IMP not specified
    2024-512330-15-00 1 country 2025 n=56
    Ended

Other

1 trial
  • Angelini Pharma Italia Aziende Chimiche Riunite Angelini Francesc O A.C.R.A.F. S.p.A. Commercial
    IMP not specified
    2024-511612-24-00 1 country 2024 n=64
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Lophora ApS Commercial 1 Phase I 0
Angelini Pharma Italia Aziende Chimiche Riunite Angelini Francesc O A.C.R.A.F. S.p.A. Commercial 1 Other 0
Centre Hospitalier Universitaire Grenoble Alpes Academic 1 Phase II 0
Fondazione Policlinico Universitario Agostino Gemelli IRCCS Academic 1 Phase II 1
Narodni Ustav Dusevniho Zdravi Academic 1 Phase II 1
University Of Gothenburg Academic 1 Phase II 0
Azienda Socio Sanitaria Territoriale Di Lodi Academic 1 Phase IV 1
New trials by year
2022
1
2024
2
2025
2
← All indication landscapes